社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
adriandino
IP属地：未知
+关注
帖子 · 75
帖子 · 75
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
adriandino
adriandino
·
2021-12-22
Wow
BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>
BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers
BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>
看
3,116
回复
1
点赞
3
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-12-05
Buy
非常抱歉，此主贴已删除
看
3,790
回复
评论
点赞
4
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-12-03
Up?
Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>
Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading. After comple
Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>
看
4,170
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-11-12
Liked
Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>
SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quar
Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>
看
3,610
回复
1
点赞
6
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-11-04
Oh no
Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>
Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea
Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>
看
3,206
回复
评论
点赞
5
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-10-19
Buy buy buy
Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>
Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that wo
Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>
看
3,220
回复
评论
点赞
6
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-10-13
Buy buy buy
非常抱歉，此主贴已删除
看
2,970
回复
评论
点赞
3
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-10-11
Buy buy buy
非常抱歉，此主贴已删除
看
3,589
回复
评论
点赞
2
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-09-28
Buy buy buy
非常抱歉，此主贴已删除
看
4,225
回复
1
点赞
4
编组 21备份 2
分享
举报
adriandino
adriandino
·
2021-09-27
Buy buy buy
非常抱歉，此主贴已删除
看
3,184
回复
评论
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3557838603033373","uuid":"3557838603033373","gmtCreate":1594744580157,"gmtModify":1619438267726,"name":"adriandino","pinyin":"adriandino","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":501,"tweetSize":75,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"93.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.11%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691683902,"gmtCreate":1640183692823,"gmtModify":1640183760969,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691683902","repostId":"1165830356","repostType":2,"repost":{"id":"1165830356","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640183188,"share":"https://www.laohu8.com/m/news/1165830356?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:26","market":"us","language":"en","title":"BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165830356","media":"Benzinga","summary":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the Univers","content":"<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody<blockquote>BiondVax计划获得纳米级COVID-19抗体许可后股价飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-22 22:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>BiondVax Pharmaceuticals Ltd</b> has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.</p><p><blockquote><b>BiondVax制药有限公司</b>已与德国马克斯·普朗克学会和哥廷根大学医学中心签订协议。</blockquote></p><p> <ul> <li>The parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.</li> <li>VHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).</li> <li>These include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.</li> <li>The collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.</li> <li>The candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.</li> <li>BiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.</li> <li>The parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.</li> <li><b>Price Action:</b> BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.</li> </ul></p><p><blockquote><ul><li>双方打算开展为期5年的战略研究合作，包括BiondVax许可VHH抗体的选项。</li><li>VHH抗体由马克斯·普朗克研究所开发，表现出优于当前行业标准人单克隆抗体(mAb)的关键优势。</li><li>这些包括与较小靶位点结合的能力、与靶显著更高的亲和力、更高的稳定性、易于和更低的制造成本以及改善患者安全性的潜力。</li><li>此次合作将从授权BiondVax的全球独家COVID-19 VHH候选抗体开始。</li><li>这些候选药物已被证明可以中和所有已知的主要变异体，药物浓度比目前的新冠肺炎单克隆抗体低约100倍。</li><li>BiondVax预计将于2022年完成临床前概念验证吸入研究，并于2023年启动人体临床试验。</li><li>双方的目标是在90天内完成最终协议，尽管无法保证双方是否以及何时会执行最终协议。</li><li><b>价格走势：</b>周三最后一次盘前交易中，BVXV股价上涨98.7%，至2.94美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165830356","content_text":"BiondVax Pharmaceuticals Ltd has entered into agreements with the Max Planck Society and the University Medical Center Göttingen in Germany.\n\nThe parties intend to enter into a 5-year strategic research collaboration, including an option for BiondVax to license VHH antibodies.\nVHH antibodies were developed by the Max Planck Institute and exhibit key advantages over current industry-standard human monoclonal antibodies (mAbs).\nThese include the ability to bind to smaller target sites, significantly higher affinity to the target, higher stability, ease & lower manufacturing cost, and potential for improved patient safety.\nThe collaboration will begin with licensing BiondVax's exclusive worldwide COVID-19 VHH antibody candidates.\nThe candidates have been shown to neutralize all known major variants of concern at around 100-times lower drug concentrations than current COVID-19 mAbs.\nBiondVax anticipates completing preclinical proof-of-concept inhalation studies in 2022 and initiating human clinical trials in 2023.\nThe parties aim to complete definitive agreements within 90 days, although there is no guarantee if and when the parties will execute the final agreements.\nPrice Action: BVXV shares are up 98.7% at $2.94 during the premarket session on the last check Wednesday.","news_type":1,"symbols_score_info":{"BVXV":0.9}},"isVote":1,"tweetType":1,"viewCount":3116,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608690847,"gmtCreate":1638701123059,"gmtModify":1638701123059,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy","listText":"Buy","text":"Buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608690847","repostId":"2188528084","repostType":4,"isVote":1,"tweetType":1,"viewCount":3790,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601292988,"gmtCreate":1638531326683,"gmtModify":1638531350519,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Up?","listText":"Up?","text":"Up?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601292988","repostId":"1166348149","repostType":4,"repost":{"id":"1166348149","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638522212,"share":"https://www.laohu8.com/m/news/1166348149?lang=zh_CN&edition=full","pubTime":"2021-12-03 17:03","market":"us","language":"en","title":"Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1166348149","media":"Tiger Newspress","summary":"Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.\n\nAfter comple","content":"<p>Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.</p><p><blockquote>Grab股价在首日交易暴跌20%后，在盘前交易中上涨7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1ecbac0018debb2d6e75a60d1c7f3d1\" tg-width=\"853\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> After completing the richest deal yet for a special-purpose acquisition company,Grab Holdings Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.</p><p><blockquote>Grab Holdings Ltd.在完成了特殊目的收购公司迄今为止最富有的交易后。周四，即在美国交易的第一天，该股经历了最初的上涨，但随后暴跌至20%以上的跌幅。</blockquote></p><p> The Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.</p><p><blockquote>这家总部位于新加坡的公司开发了一款“超级应用”，在东南亚400多个城市提供叫车、送货和金融服务。Grab首席财务官Peter Oey周四在接受采访时表示，由于东南亚（尤其是越南）与COVID-19相关的停工，该公司在截至9月30日的第三季度经历了“最艰难的时期”。但他指出，尽管该公司正在关注新型冠状病毒变种奥密克戎的情况，但预计增长和复苏仍将持续。</blockquote></p><p> Backers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp. and SoftBank Group Corp.'s Vision Fund.</p><p><blockquote>Grab成立于2012年，其支持者包括滴滴出行、丰田汽车和软银集团的愿景基金。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab stock rallied 7% in premarket trading<blockquote>Grab股价在盘前交易中上涨7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-03 17:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.</p><p><blockquote>Grab股价在首日交易暴跌20%后，在盘前交易中上涨7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f1ecbac0018debb2d6e75a60d1c7f3d1\" tg-width=\"853\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> After completing the richest deal yet for a special-purpose acquisition company,Grab Holdings Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.</p><p><blockquote>Grab Holdings Ltd.在完成了特殊目的收购公司迄今为止最富有的交易后。周四，即在美国交易的第一天，该股经历了最初的上涨，但随后暴跌至20%以上的跌幅。</blockquote></p><p> The Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.</p><p><blockquote>这家总部位于新加坡的公司开发了一款“超级应用”，在东南亚400多个城市提供叫车、送货和金融服务。Grab首席财务官Peter Oey周四在接受采访时表示，由于东南亚（尤其是越南）与COVID-19相关的停工，该公司在截至9月30日的第三季度经历了“最艰难的时期”。但他指出，尽管该公司正在关注新型冠状病毒变种奥密克戎的情况，但预计增长和复苏仍将持续。</blockquote></p><p> Backers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp. and SoftBank Group Corp.'s Vision Fund.</p><p><blockquote>Grab成立于2012年，其支持者包括滴滴出行、丰田汽车和软银集团的愿景基金。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166348149","content_text":"Grab stock rallied 7% in premarket trading after plunging 20% on first day of trading.\n\nAfter completing the richest deal yet for a special-purpose acquisition company,Grab Holdings Ltd. shares experienced an initial pop Thursday, their first day of trading in the U.S., but then slumped to a decline of more than 20%.\nThe Singapore-based company makes a \"superapp\" offering ride-hailing, delivery and financial services in more than 400 cities in Southeast Asia. Grab's chief financial officer, Peter Oey, said in an interview on Thursday that the company had its \"roughest patch\" in the third quarter ended Sept. 30 because of COVID-19-related shutdowns in Southeast Asia, especially Vietnam. But he pointed to continued expected growth and recovery, even as the company watches what happens with the new coronavirus variant, omicron.\nBackers of Grab, which was founded in 2012, include Didi Global Inc, Toyota Motor Corp. and SoftBank Group Corp.'s Vision Fund.","news_type":1,"symbols_score_info":{"GRAB":0.9}},"isVote":1,"tweetType":1,"viewCount":4170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879637577,"gmtCreate":1636715008912,"gmtModify":1636715009013,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Liked","listText":"Liked","text":"Liked","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879637577","repostId":"1149394295","repostType":4,"repost":{"id":"1149394295","kind":"news","pubTimestamp":1636714672,"share":"https://www.laohu8.com/m/news/1149394295?lang=zh_CN&edition=full","pubTime":"2021-11-12 18:57","market":"us","language":"en","title":"Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149394295","media":"Reuters","summary":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quar","content":"<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p><p><blockquote>路透圣保罗11月12日-巴西化妆品制造商Natura&Co报告季度净利润下降28.5%，至2.729亿雷亚尔（合5045万美元），同时还宣布了一项新的股票回购计划以及在纽约上市的潜在计划。</blockquote></p><p> Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p><p><blockquote>Natura group首席执行官罗伯托·马克斯(Roberto Marques)表示，很难将业绩与2020年同期进行比较，当时该公司增长了20%以上，但他指出，今年迄今为止，与前相比，该公司的表现仍然优于行业。-大流行水平。</blockquote></p><p> The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p><p><blockquote>该公司拥有雅芳、美体小铺和伊索等品牌，周四晚间表示，第三季度调整后息税折旧摊销前利润(EBITDA)达到8.19亿雷亚尔，同比下降47%。</blockquote></p><p> It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p><p><blockquote>其EBITDA利润率为8.6%，同比下降620个基点。</blockquote></p><p> Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p><p><blockquote>Natura正在启动一项高达15亿雷亚尔的新股票回购计划，并正在评估将其主要上市地点转移到纽约证券交易所，以反映其日益全球化的性质。</blockquote></p><p> On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p><p><blockquote>关于回购计划，马克斯告诉路透社，公司认为这是为股东创造价值的好机会。</blockquote></p><p> He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p><p><blockquote>他赞扬雅芳品牌在连续五年下降后，销售额在2021年9个月内首次实现增长。</blockquote></p><p> Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p><p><blockquote>Marques表示，Natura的季度业绩受到全球供应链中断、通货膨胀和多个市场外汇贬值的影响，估计对EBITDA利润率的影响约为5个百分点。</blockquote></p><p> According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p><p><blockquote>马克斯表示，由于主要市场都在处理这些问题，Natura很难提高价格。</blockquote></p><p> \"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p><p><blockquote>“我们的一些市场正面临高失业率，提高价格的能力受到损害……这是一个复杂的等式，”马克斯说。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatura &Co posts $50 mln quarterly profit; plans share buyback, listing switch<blockquote>Natura&Co公布季度利润5000万美元；计划股票回购、上市转换</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-12 18:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.</p><p><blockquote>路透圣保罗11月12日-巴西化妆品制造商Natura&Co报告季度净利润下降28.5%，至2.729亿雷亚尔（合5045万美元），同时还宣布了一项新的股票回购计划以及在纽约上市的潜在计划。</blockquote></p><p> Natura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.</p><p><blockquote>Natura group首席执行官罗伯托·马克斯(Roberto Marques)表示，很难将业绩与2020年同期进行比较，当时该公司增长了20%以上，但他指出，今年迄今为止，与前相比，该公司的表现仍然优于行业。-大流行水平。</blockquote></p><p> The company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.</p><p><blockquote>该公司拥有雅芳、美体小铺和伊索等品牌，周四晚间表示，第三季度调整后息税折旧摊销前利润(EBITDA)达到8.19亿雷亚尔，同比下降47%。</blockquote></p><p> It reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.</p><p><blockquote>其EBITDA利润率为8.6%，同比下降620个基点。</blockquote></p><p> Natura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.</p><p><blockquote>Natura正在启动一项高达15亿雷亚尔的新股票回购计划，并正在评估将其主要上市地点转移到纽约证券交易所，以反映其日益全球化的性质。</blockquote></p><p> On the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.</p><p><blockquote>关于回购计划，马克斯告诉路透社，公司认为这是为股东创造价值的好机会。</blockquote></p><p> He praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.</p><p><blockquote>他赞扬雅芳品牌在连续五年下降后，销售额在2021年9个月内首次实现增长。</blockquote></p><p> Marques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.</p><p><blockquote>Marques表示，Natura的季度业绩受到全球供应链中断、通货膨胀和多个市场外汇贬值的影响，估计对EBITDA利润率的影响约为5个百分点。</blockquote></p><p> According to Marques, Natura has had a hard time raising prices as key markets deal with these issues.</p><p><blockquote>马克斯表示，由于主要市场都在处理这些问题，Natura很难提高价格。</blockquote></p><p> \"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.</p><p><blockquote>“我们的一些市场正面临高失业率，提高价格的能力受到损害……这是一个复杂的等式，”马克斯说。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NTCO":"Natura & Co Holding SA"},"source_url":"https://finance.yahoo.com/news/natura-co-posts-50-mln-103410238.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149394295","content_text":"SAO PAULO, Nov 12 (Reuters) - Brazilian cosmetics maker Natura &Co has reported a 28.5% drop in quarterly net income to 272.9 million reais ($50.45 million) while also announcing a new share buyback program and potential plans to list its shares in New York.\nNatura group CEO Roberto Marques said it was tough to compare the results with the same period of 2020, when the firm grew by more than 20%, but noted it has still outperformed the industry on a year-to-date basis and versus pre-pandemic levels.\nThe company, which owns brands like Avon, The Body Shop and Aesop, said late on Thursday its adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached 819 million reais in the third quarter - a drop of 47% from a year ago.\nIt reported an EBITDA margin of 8.6%, down 620 basis points year-on-year.\nNatura is launching a new share buyback program of up to 1.5 billion reais and evaluating switching its primary listing to the New York Stock Exchange to reflect its increasingly global nature.\nOn the buyback plan, Marques told Reuters that the company sees it as a good opportunity to create value for its shareholders.\nHe praised the Avon brand for reaching its first growth in sales during a nine-month period in 2021, after falling for five years in a row.\nMarques said Natura's quarterly results were affected by global supply chain disruptions, inflation and foreign exchange depreciation in several markets, estimating an impact of about 5 percentage points on EBITDA margin.\nAccording to Marques, Natura has had a hard time raising prices as key markets deal with these issues.\n\"Some of our markets are facing high unemployment levels, and the ability to raise prices gets compromised... It is a complex equation,\" Marques said.","news_type":1,"symbols_score_info":{"NTCO":0.9}},"isVote":1,"tweetType":1,"viewCount":3610,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848447407,"gmtCreate":1636024166653,"gmtModify":1636024166821,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848447407","repostId":"1101079537","repostType":4,"repost":{"id":"1101079537","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636023902,"share":"https://www.laohu8.com/m/news/1101079537?lang=zh_CN&edition=full","pubTime":"2021-11-04 19:05","market":"us","language":"en","title":"Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101079537","media":"Tiger Newspress","summary":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed ea","content":"<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna下调了今年Covid-19疫苗销售预期，第三季度盈利和收入未达到预期，股价暴跌9%。</blockquote></p><p> <ul> <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul> <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna第三季度营收为49.69亿美元，去年同期为1.57亿美元；FactSet共识62亿美元；</li></ul><ul><li>Moderna第三季度每股收益7.70美元，而一年前每股亏损59美分；FactSet共识9.09美元；</li></ul></blockquote></p><p> Moderna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天报告了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入50亿美元，净利润33亿美元，稀释后每股收益7.70美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国FDA授予Moderna新冠疫苗生物制品许可申请优先审查</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中进行的2/3期KidCOVE研究的中期数据显示，在50 μ g剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺部治疗方式：Vertex和现代囊性纤维化mRNA治疗剂(VXc-522)正在进行首次人体研究</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有37个项目正在开发中，其中21个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最近的进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗研发</i></blockquote></p><p> <ul> <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li> <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li> <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li> <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>现代新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）美国食品和药物管理局(U.S.FDA)以及欧盟委员会和SwissMedic批准50µg剂量水平的Moderna COVID-19疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>mRNA-1273在6岁至12岁以下儿童中的2/3期KidCOVE研究的新数据显示，使用3期COVE研究COVID-19的主要病例定义，在50µg剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</li><li>针对新冠肺炎的下一代候选疫苗（mRNA-1283）的1期研究已全面入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul> <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li> <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li> <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感候选疫苗（mRNA-1010）1/2期研究的1期部分已全面入组，该研究的2期部分正在筹备中</li><li>老年人呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）的关键2/3期研究预计将于2021年开始；研究预计将招募约34,000名参与者，但须与监管机构达成协议</li><li>新型联合呼吸道疫苗：Moderna COVID-19疫苗+流感候选疫苗（mRNA-1073）和儿科RSV+hMPV候选疫苗（mRNA-1365）</li></ul><i>潜在疫苗</i></blockquote></p><p> <ul> <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li> <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li> <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</li><li>EBV候选疫苗（mRNA-1189）的1期研究预计即将开始</li><li>新型EBV治疗候选疫苗（mRNA-1195）</li></ul><i>治疗学</i></blockquote></p><p> <ul> <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li> <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li> <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li> <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li> <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li> <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默克公司的派姆单抗（KEYTRUDA®），与帕博利珠单抗单药相比，用于高危切除黑色素瘤的辅助治疗已完全入组；预计将于2022年第四季度公布数据</li><li>丙酸血症候选药物（mRNA-3927）1/2期PARAMOUNT研究首个队列的入组已完成</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）1期研究中的首例患者给药</li><li>美国FDA授予GSD1a项目(mRNA-3745)的新药研究申请(IND)开放和孤儿药资格</li><li>向改变生活药物研究所（ILCM）免费提供研究性mRNA克里格勒-纳贾尔综合征1型（CN-1）疗法（mRNA-3351）；CN-1是一种极其罕见的疾病</li><li>介绍吸入性肺部治疗模式；Vertex和ModernaRNA囊性纤维化(CF)治疗剂(VXc-522)的首次人体研究正在以新的肺部模式进行</li></ul>Moderna继续扩大规模，目前有37个项目正在开发中，涉及34个开发候选项目1，其中21个项目正在进行临床研究。该公司更新的管道可在www.modernatx.com/pipeline.moderna上找到，合作者已发表近100篇同行评审手稿。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新财务框架</b></blockquote></p><p></p><p> <ul> <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li> <li></li> <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li> <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li> <li><b>2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li> <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li> <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li> <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年(FY)的预期交付：</b>预计2021财年产品销售额将在150亿美元至180亿美元之间。</li><li></li><li><b>2021财年疫苗剂量交付：</b>该公司预计2021财年100µg剂量水平的COVID-19疫苗的交付量将在7亿至8亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期较长（可能将交付时间推迟到2022年初）、灌装/精加工产能扩张以及产品投放市场的增加带来的暂时影响。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售额的百分比预计在16-17%之间。</li><li><b>2021年研发(R&D)以及销售、一般和行政(SG&A)费用：</b>随着商业和研发活动及费用的增加，预计2021年研发和SG&A费用的成本将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合以及23亿美元累计净运营亏损结转的利用，该公司目前预计2021年的有效税率将处于高个位数范围。</li><li><b>资本开支：</b>预计2021年资本投资约为4亿美元。</li><li><b>股份回购计划：</b>董事会已授权在两年内实施高达10亿美元的股票回购计划，以向股东返还多余资本。截至第三季度末，没有回购任何股票。</li></ul><b>2022年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计有几种动态将推动2022年的收入：</blockquote></p><p> <ul> <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li> <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li> <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署人：</b>该公司已签署约170亿美元的预购协议(APA)，将于2022年交付。</li><li><b>带选项的APA：</b>该公司预计根据2022年APA行使的期权金额高达30亿美元。</li><li><b>美国。2022年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的BLA或sBLA，该公司预计商业助推器市场销售额可能高达20亿美元。</li></ul>基于这三个收入驱动因素，该公司认为2022年销售额可能在170亿至220亿美元之间。该公司继续与各国政府和国际组织（包括COVAX、泛美卫生组织(PAHO)和非洲联盟）讨论2022年APA。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock plunged 9% after reporting quarterly results<blockquote>Moderna公布季度业绩后股价暴跌9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-04 19:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.</p><p><blockquote>Moderna下调了今年Covid-19疫苗销售预期，第三季度盈利和收入未达到预期，股价暴跌9%。</blockquote></p><p> <ul> <li>Moderna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;</li> </ul> <ul> <li>Moderna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;</li> </ul> <img src=\"https://static.tigerbbs.com/2e0e9dd869aaa4060fdee9429041a910\" tg-width=\"847\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote><ul><li>Moderna第三季度营收为49.69亿美元，去年同期为1.57亿美元；FactSet共识62亿美元；</li></ul><ul><li>Moderna第三季度每股收益7.70美元，而一年前每股亏损59美分；FactSet共识9.09美元；</li></ul></blockquote></p><p> Moderna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.</p><p><blockquote>Moderna，Inc.今天报告了2021财年第三季度的财务业绩并提供了业务更新。</blockquote></p><p> <i>Q3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70</i></p><p><blockquote><i>第三季度总收入50亿美元，净利润33亿美元，稀释后每股收益7.70美元</i></blockquote></p><p> <i>U.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine</i></p><p><blockquote><i>美国FDA授予Moderna新冠疫苗生物制品许可申请优先审查</i></blockquote></p><p> <i>Interim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level</i></p><p><blockquote><i>mRNA-1273在6至12岁以下儿童中进行的2/3期KidCOVE研究的中期数据显示，在50 μ g剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</i></blockquote></p><p> <i>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</i></p><p><blockquote><i>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</i></blockquote></p><p> <i>Introducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing</i></p><p><blockquote><i>介绍吸入性肺部治疗方式：Vertex和现代囊性纤维化mRNA治疗剂(VXc-522)正在进行首次人体研究</i></blockquote></p><p> <i>Company continues to scale with 37 programs in development, including 21 in ongoing clinical studies</i></p><p><blockquote><i>公司继续扩大规模，有37个项目正在开发中，其中21个项目正在进行临床研究</i></blockquote></p><p> <b>Updates and recent progress include:</b></p><p><blockquote><b>更新和最近的进展包括：</b></blockquote></p><p> <i>COVID-19 Vaccine Development</i></p><p><blockquote><i>COVID-19疫苗研发</i></blockquote></p><p> <ul> <li>Moderna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level</li> <li>U.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine</li> <li>New data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19</li> <li>The Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine</li> </ul> <i>Respiratory Vaccines</i></p><p><blockquote><ul><li>现代新冠肺炎疫苗（SpikevaxTM）：获得美国紧急使用授权（EUA）美国食品和药物管理局(U.S.FDA)以及欧盟委员会和SwissMedic批准50µg剂量水平的Moderna COVID-19疫苗加强剂量</li><li>美国FDA授予Moderna COVID-19疫苗生物制品许可申请（BLA）优先审查</li><li>mRNA-1273在6岁至12岁以下儿童中的2/3期KidCOVE研究的新数据显示，使用3期COVE研究COVID-19的主要病例定义，在50µg剂量水平的mRNA-1273首次给药后两周，疫苗效力为100%</li><li>针对新冠肺炎的下一代候选疫苗（mRNA-1283）的1期研究已全面入组；Moderna预计很快开始mRNA-1283的2期研究；mRNA-1283正在被开发为一种潜在的冰箱稳定mRNA疫苗</li></ul><i>呼吸道疫苗</i></blockquote></p><p> <ul> <li>Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing</li> <li>Pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities</li> <li>New combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)</li> </ul> <i>Latent Vaccines</i></p><p><blockquote><ul><li>四价季节性流感候选疫苗（mRNA-1010）1/2期研究的1期部分已全面入组，该研究的2期部分正在筹备中</li><li>老年人呼吸道合胞病毒（RSV）候选疫苗（mRNA-1345）的关键2/3期研究预计将于2021年开始；研究预计将招募约34,000名参与者，但须与监管机构达成协议</li><li>新型联合呼吸道疫苗：Moderna COVID-19疫苗+流感候选疫苗（mRNA-1073）和儿科RSV+hMPV候选疫苗（mRNA-1365）</li></ul><i>潜在疫苗</i></blockquote></p><p> <ul> <li>First participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)</li> <li>Phase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon</li> <li>New EBV therapeutic vaccine candidate (mRNA-1195)</li> </ul> <i>Therapeutics</i></p><p><blockquote><ul><li>巨细胞病毒(CMV)候选疫苗(mRNA-1647)3期研究中的第一批参与者接受给药</li><li>EBV候选疫苗（mRNA-1189）的1期研究预计即将开始</li><li>新型EBV治疗候选疫苗（mRNA-1195）</li></ul><i>治疗学</i></blockquote></p><p> <ul> <li>Phase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022</li> <li>Enrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete</li> <li>First patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)</li> <li>Investigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)</li> <li>Providing investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease</li> <li>Introducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality</li> </ul> Moderna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.</p><p><blockquote><ul><li>个性化癌症疫苗（PCV）（mRNA-4157）联合默克公司的派姆单抗（KEYTRUDA®），与帕博利珠单抗单药相比，用于高危切除黑色素瘤的辅助治疗已完全入组；预计将于2022年第四季度公布数据</li><li>丙酸血症候选药物（mRNA-3927）1/2期PARAMOUNT研究首个队列的入组已完成</li><li>甲基丙二酸血症（MMA）候选药物（mRNA-3705）1期研究中的首例患者给药</li><li>美国FDA授予GSD1a项目(mRNA-3745)的新药研究申请(IND)开放和孤儿药资格</li><li>向改变生活药物研究所（ILCM）免费提供研究性mRNA克里格勒-纳贾尔综合征1型（CN-1）疗法（mRNA-3351）；CN-1是一种极其罕见的疾病</li><li>介绍吸入性肺部治疗模式；Vertex和ModernaRNA囊性纤维化(CF)治疗剂(VXc-522)的首次人体研究正在以新的肺部模式进行</li></ul>Moderna继续扩大规模，目前有37个项目正在开发中，涉及34个开发候选项目1，其中21个项目正在进行临床研究。该公司更新的管道可在www.modernatx.com/pipeline.moderna上找到，合作者已发表近100篇同行评审手稿。</blockquote></p><p> <b>2021 Updated Financial Framework</b></p><p><blockquote><b>2021年更新财务框架</b></blockquote></p><p></p><p> <ul> <li><b>For Expected Delivery in Fiscal Year (FY) 2021:</b>Expected to realize product sales for FY 2021 between$15 billionand$18 billion.</li> <li></li> <li><b>Vaccine Dose Deliveries for FY 2021:</b>The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.</li> <li><b>Cost of Sales:</b>Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.</li> <li><b>2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:</b>Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.</li> <li><b>Tax Rate:</b>The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.</li> <li><b>Capital Expenditures:</b>Expect approximately$0.4 billionof capital investments for 2021.</li> <li><b>Share Repurchase Program:</b>The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.</li> </ul> <b>2022 Revenue Drivers</b></p><p><blockquote><ul><li><b>对于2021财年(FY)的预期交付：</b>预计2021财年产品销售额将在150亿美元至180亿美元之间。</li><li></li><li><b>2021财年疫苗剂量交付：</b>该公司预计2021财年100µg剂量水平的COVID-19疫苗的交付量将在7亿至8亿剂之间。影响产量的关键变量包括国际运输和出口的交付周期较长（可能将交付时间推迟到2022年初）、灌装/精加工产能扩张以及产品投放市场的增加带来的暂时影响。</li><li><b>销售成本：</b>2021财年，销售成本占产品销售额的百分比预计在16-17%之间。</li><li><b>2021年研发(R&D)以及销售、一般和行政(SG&A)费用：</b>随着商业和研发活动及费用的增加，预计2021年研发和SG&A费用的成本将逐季增加。</li><li><b>税率：</b>由于预测的全球销售组合以及23亿美元累计净运营亏损结转的利用，该公司目前预计2021年的有效税率将处于高个位数范围。</li><li><b>资本开支：</b>预计2021年资本投资约为4亿美元。</li><li><b>股份回购计划：</b>董事会已授权在两年内实施高达10亿美元的股票回购计划，以向股东返还多余资本。截至第三季度末，没有回购任何股票。</li></ul><b>2022年收入驱动因素</b></blockquote></p><p> They expect several dynamics will drive 2022 revenues:</p><p><blockquote>他们预计有几种动态将推动2022年的收入：</blockquote></p><p> <ul> <li><b>APAs Signed:</b>The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.</li> <li><b>APAs with Options:</b>The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.</li> <li><b>U.S.Fall 2022 Booster Market:</b>Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.</li> </ul> Based on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.</p><p><blockquote><ul><li><b>APA签署人：</b>该公司已签署约170亿美元的预购协议(APA)，将于2022年交付。</li><li><b>带选项的APA：</b>该公司预计根据2022年APA行使的期权金额高达30亿美元。</li><li><b>美国。2022年秋季助推器市场：</b>如果在秋季助推器季节之前收到助推器的BLA或sBLA，该公司预计商业助推器市场销售额可能高达20亿美元。</li></ul>基于这三个收入驱动因素，该公司认为2022年销售额可能在170亿至220亿美元之间。该公司继续与各国政府和国际组织（包括COVAX、泛美卫生组织(PAHO)和非洲联盟）讨论2022年APA。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101079537","content_text":"Moderna stock plunged 9% after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.\n\nModerna Q3 revenue $4.969 bln vs. $157 mln a year ago; FactSet consensus $6.200 bln;\n\n\nModerna Q3 EPS $7.70 vs loss 59 cents a share a year ago; FactSet consensus $9.09;\n\n\nModerna, Inc. today reported financial results and provided business updates for the third quarter of fiscal year 2021.\nQ3 total revenue of$5.0 billion, net income of$3.3 billionand diluted EPS of$7.70\nU.S.FDA granted Priority Review to the Biologics License Application for Moderna’s COVID-19 vaccine\nInterim data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nIntroducing inhaled pulmonary therapeutics modality:Vertex andModernacystic fibrosis mRNA therapeutic (VXc-522) IND-enabling first-in-human studies ongoing\nCompany continues to scale with 37 programs in development, including 21 in ongoing clinical studies\nUpdates and recent progress include:\nCOVID-19 Vaccine Development\n\nModerna COVID-19 Vaccine (SpikevaxTM): Received Emergency Use Authorization (EUA) from theU.S. Food and Drug Administration(U.S.FDA), and approvals by theEuropean CommissionandSwissmedicfor a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level\nU.S.FDA granted Priority Review to the Biologics License Application (BLA) for the Moderna COVID-19 vaccine\nNew data from Phase 2/3 KidCOVE study of mRNA-1273 in children ages 6 to under 12 years shows vaccine efficacy of 100% two weeks after first dose of mRNA-1273 at 50 µg dose level, using the Phase 3 COVE study primary case definition for COVID-19\nThe Phase 1 study of next-generation vaccine candidate against COVID-19 (mRNA-1283) is fully enrolled;Modernaexpects to begin Phase 2 study of mRNA-1283 soon; mRNA-1283 is being developed as a potential refrigerator-stable mRNA vaccine\n\nRespiratory Vaccines\n\nPhase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing\nPivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; study expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities\nNew combination respiratory vaccines: Moderna COVID-19 vaccine + flu vaccine candidate (mRNA-1073) and pediatric RSV + hMPV vaccine candidate (mRNA-1365)\n\nLatent Vaccines\n\nFirst participants dosed in Phase 3 study of cytomegalovirus (CMV) vaccine candidate (mRNA-1647)\nPhase 1 study of EBV vaccine candidate (mRNA-1189)expected to start soon\nNew EBV therapeutic vaccine candidate (mRNA-1195)\n\nTherapeutics\n\nPhase 2 randomized, placebo-controlled study of personalized cancer vaccine (PCV) (mRNA-4157) in combination with Merck’s pembrolizumab (KEYTRUDA®), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is fully enrolled; data readout expected in the fourth quarter of 2022\nEnrollment of the first cohort in Propionic Acidemia candidate (mRNA-3927) Phase 1/2Paramountstudy is complete\nFirst patient dosed in Phase 1 study of Methylmalonic Acidemia (MMA) candidate (mRNA-3705)\nInvestigational New Drug application (IND) open and Orphan Drug Designation granted byU.S.FDA for GSD1a program (mRNA-3745)\nProviding investigational mRNA Crigler-Najjar Syndrome Type 1 (CN-1) therapy (mRNA-3351) toInstitute for Life Changing Medicines(ILCM) free of charge; CN-1 is an ultra-rare disease\nIntroducing inhaled pulmonary therapeutics modality; IND-enabling first-in-human studies of Vertex andModernamRNA cystic fibrosis (CF) therapeutic (VXc-522) are ongoing in new pulmonary modality\n\nModerna continues to scale, now with 37 programs in development across 34 development candidates1, including 21 in ongoing clinical studies. The Company’s updated pipeline can be found atwww.modernatx.com/pipeline.Modernaand collaborators have published nearly 100 peer reviewed manuscripts.\n2021 Updated Financial Framework\n\nFor Expected Delivery in Fiscal Year (FY) 2021:Expected to realize product sales for FY 2021 between$15 billionand$18 billion.\n\nVaccine Dose Deliveries for FY 2021:The Company expects deliveries of its COVID-19 vaccine in FY 2021 to be between 700 million and 800 million doses at the 100 µg dose level. Key variables impacting output include longer delivery lead times for international shipments and exports that may shift deliveries to early 2022, temporary impact from expansion of fill/finish capacity and ramp up of product release to market.\nCost of Sales:Cost of sales as percentage of product sales are expected to be between 16-17% for FY 2021.\n2021 Research & Development (R&D) and Selling, General & Administrative (SG&A) Expenses:Continue to expect quarter over quarter cost increases in R&D and SG&A expenses during 2021 as commercial and research and development activities and expenses ramp up.\nTax Rate:The Company now expects the effective tax rate for 2021 to be in the high single digit range as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of$2.3 billion.\nCapital Expenditures:Expect approximately$0.4 billionof capital investments for 2021.\nShare Repurchase Program:The Board of Directors has authorized a share repurchase program of up to$1 billionover a two-year period to return excess capital to shareholders. No shares were repurchased through the end of the third quarter.\n\n2022 Revenue Drivers\nThey expect several dynamics will drive 2022 revenues:\n\nAPAs Signed:The Company has signed approximately$17 billionof advance purchase agreements (APAs) for delivery in 2022.\nAPAs with Options:The Company anticipates the exercise of options under 2022 APAs of up to$3 billion.\nU.S.Fall 2022 Booster Market:Subject to receipt of a BLA or sBLA for boosters prior to the fall booster season, the Company anticipates commercial booster market sales could be up to$2 billion.\n\nBased on these three revenue drivers, the Company believes 2022 sales could be in the range of$17 billionto$22 billion. The Company continues to have discussions for 2022 APAs with governments and international organizations, including COVAX, thePan American Health Organization(PAHO) and theAfrican Union.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3206,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859021205,"gmtCreate":1634641639710,"gmtModify":1634641747081,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859021205","repostId":"1111431743","repostType":4,"repost":{"id":"1111431743","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1634637193,"share":"https://www.laohu8.com/m/news/1111431743?lang=zh_CN&edition=full","pubTime":"2021-10-19 17:53","market":"hk","language":"en","title":"Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111431743","media":"Benzinga","summary":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that wo","content":"<p>Chinese e-commerce giant <b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.</p><p><blockquote>中国电商巨头<b><a href=\"https://laohu8.com/S/BABA\">阿里巴巴-SW</a></b>周二确认了开发内部处理器的计划，该处理器将用于为其云计算业务提供动力。</blockquote></p><p> <b>What Happened:</b> The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p><p><blockquote><b>发生了什么：</b>倚天710服务器芯片由阿里巴巴-SW内部半导体部门T-Head开发。</blockquote></p><p> The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p><p><blockquote>该设计基于英国芯片制造商Arm Holding的架构，将使用5nm技术，该技术自2019年以来一直在开发中，预计将通过利用性能和能效来推动阿里巴巴-SW的云服务。</blockquote></p><p> <b>Why It Matters:</b> The semiconductor foray replicates similar moves from rival computing players such as <b>Huawei Technologies</b> and <b>Amazon.com Inc.</b></p><p><blockquote><b>为什么重要：</b>此次半导体进军复制了竞争对手计算公司的类似举措，例如<b>华为技术</b>和<b>亚马逊公司。</b></blockquote></p><p> Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p><p><blockquote>根据Canalys发布的报告，阿里巴巴-SW是第二季度中国最大的云供应商，其在中国云市场的份额为33.8%。</blockquote></p><p> The Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.</p><p><blockquote>在全球范围内严重的芯片短缺影响到汽车、电子应用到智能手机等行业之际，中国政府还一直敦促行业领导者投资国内芯片行业。</blockquote></p><p> <b>Price Action:</b> Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p><p><blockquote><b>价格走势：</b>阿里巴巴-SW股价周一收盘下跌0.68%，至每股166.82美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlibaba Confirms It's Developing In-House Advanced Chips To Boost Cloud Computing Business<blockquote>阿里巴巴-SW确认正在开发内部先进芯片以推动云计算业务</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-10-19 17:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Chinese e-commerce giant <b><a href=\"https://laohu8.com/S/BABA\">Alibaba</a></b> on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.</p><p><blockquote>中国电商巨头<b><a href=\"https://laohu8.com/S/BABA\">阿里巴巴-SW</a></b>周二确认了开发内部处理器的计划，该处理器将用于为其云计算业务提供动力。</blockquote></p><p> <b>What Happened:</b> The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.</p><p><blockquote><b>发生了什么：</b>倚天710服务器芯片由阿里巴巴-SW内部半导体部门T-Head开发。</blockquote></p><p> The design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.</p><p><blockquote>该设计基于英国芯片制造商Arm Holding的架构，将使用5nm技术，该技术自2019年以来一直在开发中，预计将通过利用性能和能效来推动阿里巴巴-SW的云服务。</blockquote></p><p> <b>Why It Matters:</b> The semiconductor foray replicates similar moves from rival computing players such as <b>Huawei Technologies</b> and <b>Amazon.com Inc.</b></p><p><blockquote><b>为什么重要：</b>此次半导体进军复制了竞争对手计算公司的类似举措，例如<b>华为技术</b>和<b>亚马逊公司。</b></blockquote></p><p> Alibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.</p><p><blockquote>根据Canalys发布的报告，阿里巴巴-SW是第二季度中国最大的云供应商，其在中国云市场的份额为33.8%。</blockquote></p><p> The Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.</p><p><blockquote>在全球范围内严重的芯片短缺影响到汽车、电子应用到智能手机等行业之际，中国政府还一直敦促行业领导者投资国内芯片行业。</blockquote></p><p> <b>Price Action:</b> Alibaba shares closed 0.68% lower at $166.82 a share on Monday.</p><p><blockquote><b>价格走势：</b>阿里巴巴-SW股价周一收盘下跌0.68%，至每股166.82美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111431743","content_text":"Chinese e-commerce giant Alibaba on Tuesday confirmed plans to develop an in-house processor that would be used to power its cloud computing business.\nWhat Happened: The Yitian 710 server chip is developed by Alibaba’s in-house semiconductor unit T-Head.\nThe design is based on British chipmaker Arm Holding's architecture and will use the 5nm technology, which has been under development since 2019 and is expected to boost Alibaba’s cloud services by leveraging performance and energy efficiency.\nWhy It Matters: The semiconductor foray replicates similar moves from rival computing players such as Huawei Technologies and Amazon.com Inc.\nAlibaba was the top cloud vendor in China in the second quarter and its share of the Chinese cloud market stood at 33.8%, according to a report released by Canalys.\nThe Chinese government has also been urging industry leaders to invest in the domestic chip sector amid crippling worldwide shortages affecting industries ranging from cars, electronics applications, to smartphones.\nPrice Action: Alibaba shares closed 0.68% lower at $166.82 a share on Monday.","news_type":1,"symbols_score_info":{"09988":0.9,"BABA":0.9}},"isVote":1,"tweetType":1,"viewCount":3220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826762189,"gmtCreate":1634055708286,"gmtModify":1634055782125,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826762189","repostId":"1188785088","repostType":4,"isVote":1,"tweetType":1,"viewCount":2970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":828779586,"gmtCreate":1633952916663,"gmtModify":1633952916663,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/828779586","repostId":"2174064969","repostType":4,"isVote":1,"tweetType":1,"viewCount":3589,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862950901,"gmtCreate":1632832381619,"gmtModify":1632832381719,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862950901","repostId":"2170670597","repostType":4,"isVote":1,"tweetType":1,"viewCount":4225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866605070,"gmtCreate":1632757990190,"gmtModify":1632798029312,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"themes":[],"htmlText":"Buy buy buy","listText":"Buy buy buy","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866605070","repostId":"2170462612","repostType":4,"isVote":1,"tweetType":1,"viewCount":3184,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}